JLJie Liang

Jie Liang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jie Liang has a total of 268 co-authors. Here are the top co-authors by number of shared publications:

  • Bing Xu

    Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education. School of Medicine, Northwest University, Xi’an, China

    14 shared publications
  • Kaichun Wu

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China

    14 shared publications
  • Yi Chu

    State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi’an, China

    14 shared publications
  • Yanting Shi

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University

    13 shared publications
  • Di Chen

    State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases, Air Force Military Medical University, Xi’an, China

    11 shared publications
  • Mingzuo Jiang

    Department of Gastroenterology and Hepatology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China

    10 shared publications

Latest Publications

  • Clinical profiles and management strategies in older adults with mild-to-moderate ulcerative colitis: a multicenter, comparative, real-world study

    by He Gu, Chunyan Li, Jie Liang, Feng Tian, Xiaocang Cao, Yue Li, Yubei Gu, Jun Shen, Mimic Inflammatory Bowel Disease Study Group

    Clinical profiles and management strategies in older adults with mild-to-moderate ulcerative colitis: a multicenter, comparative, real-world study

  • Open Access

    Chinese expert consensus on extraintestinal manifestations of inflammatory bowel disease

    by Jie Liang, Liuqing Zhao, Jun Shen, Hong Yang, Yao He, Ling Liu, Yufang Wang, Kaichun Wu, Minhu Chen, IBD Group of Chinese Society of Gastroenterology

    Inflammatory bowel disease (IBD) is a chronic, relapsing, inflammatory condition of the gastrointestinal tract that primarily includes Crohn’s disease and ulcerative colitis. Beyond the typical gastrointestinal symptoms, IBD is frequently associated with various extraintestinal manifestations (EIMs) affecting organs such as joints, skin, eyes, and the hepatobiliary system. As the prevalence of IBD rises in China, the identification and management of EIMs have become increasingly important. However, there is currently variation among Chinese physicians in their attention to, comprehensive assessment of, and management of EIMs in IBD. Therefore, this consensus aims to provide guidance for the systematic evaluation and multidisciplinary management of IBD-associated EIMs.

  • O-GlcNAcylation of GSDMD promotes mitochondrial dysfunction and hepatocyte injury in MASLD

    by Xue Wang, Mingzuo Jiang, Ning Xie, Xinyu Chen, Weijie Wang, Suzhen Yang, Tianming Zhao, Qiongyun Chen, Feng Zhang, Lei Wang, et al.

    Clinical and Molecular Hepatology

  • Open Access

    Association Between Crohn's Disease and Pulmonary Nodule Patterns: An Inverse Probability-Weighted Analysis of Real-World Data

    by Changsheng Cai, He Gu, Chunyan Li, Jie Liang, Feng Tian, Xiaocang Cao, Yue Li, Yubei Gu, Wenbin Qin, Qi Feng, et al.

    INTRODUCTION: Crohn's disease (CD) is a systemic inflammatory disorder with potential pulmonary involvement; however, its association with pulmonary nodules and how disease phenotype, medication, and inflammation affect nodule characteristics are unclear. Using real-world data, we aimed to comprehensively assess the burden of pulmonary nodules among patients with CD, characterize their longitudinal dynamic trajectories, and identify key determinants of their imaging phenotypes. METHODS: In this retrospective multicenter cohort study of 2,009 patients with CD and 4,002 controls, we used inverse probability weighting to compare the nodule burden and its dynamics over time in a longitudinal subcohort (n = 2,956). We assessed the associations of the Montreal classification, biologics, corticosteroids, C-reactive protein, and extraintestinal manifestations with nodule features among patients with CD and explored risk factors for high-risk nodules related to CD. RESULTS: CD was associated with higher nodule counts across all subtypes (e.g., solid nodules: incidence rate ratio [IRR], 1.80; 95% confidence interval, 1.62–1.98; P < 0.001). Longitudinally, compared with controls, patients with CD experienced greater reductions in solid nodules and nodules P < 0.001) despite the slightly faster growth of persistent nodules P < 0.01). CD-related clinical factors had limited utility for predicting high-risk nodules. DISCUSSION: CD confers an increased pulmonary nodule burden with a unique dynamic evolution. Risk stratification should prioritize age and medication exposures instead of disease phenotype because phenotypic markers lack predictive value for nodule outcomes.

  • Open Access

    Sweet’s syndrome during anti-TNF therapy with successful rescue using a JAK inhibitor in refractory ulcerative colitis: a case report and literature review

    by Yanting Shi, Jingbin Ding, Wenjing Cheng, Jindan He, Yu Da, Jie Liang

    Objective: This report describes the diagnostic and therapeutic management of Sweet’s syndrome (SS) presenting as a painful forehead plaque in a patient with refractory ulcerative colitis (UC) during apparent endoscopic remission. It highlights the association between active intestinal inflammation and extraintestinal manifestations (EIMs) and evaluates the efficacy of the Janus kinase (JAK) inhibitor upadacitinib after anti-TNF therapy failure. Methods: A case study was conducted on a 60-year-old woman with refractory UC who presented with new-onset cutaneous lesions accompanied by fever. Diagnostic evaluation included skin biopsy histopathology, comprehensive microbiological cultures, serological testing, and sequential colonoscopies to assess UC activity. Results: Histopathology revealed a dense neutrophilic infiltrate highly suggestive of SS. Infectious etiologies were ruled out. Repeat colonoscopy revealed active colitis in the setting of newly diagnosed SS. After infliximab failure, upadacitinib 45 mg/day led to pain resolution within one week and complete plaque healing by week 8, with mucosal healing and normalized inflammatory markers at follow−up. Maintenance with 30 mg/day sustained remission. Conclusion: Active UC may drive severe neutrophilic EIMs such as SS, even when prior endoscopy suggests remission. Re-assessment of bowel disease activity is crucial in this context. Upadacitinib rapidly controlled both conditions in this anti−TNF−refractory case, supporting JAK inhibition for similar overlapping immune−mediated presentations.


  • Open Access

    The burden and unique patterns of extraintestinal manifestations in Chinese inflammatory bowel disease: a nationwide multicenter investigation

    by Liuqing Zhao, Zhenzhen Fan, Jindan He, Lianlian Tian, Jun Shen, Hongliang Gao, Yanjun Chen, Xiaojing Zhao, Yan-Bo Yu, Yanyun Fan, et al.

    Extraintestinal manifestations (EIMs) are a significant disease burden in inflammatory bowel disease (IBD). However, large-scale epidemiological data from the Chinese population remain scarce. This nationwide, multicenter, retrospective cross-sectional study included 2,252 adult IBD inpatients from 10 clinical centers. Data on demographics, clinical features, and EIMs were collected and analyzed using descriptive statistics and logistic regression. Of the 2252 patients, 384 (17.1%) reported at least one EIM. Among these, data on temporal sequence were available for 310 patients, of whom 70 (22.6%) developed their first EIM before the onset of intestinal symptoms. The overall prevalence of EIMs was significantly higher in Crohn's disease (CD) than in ulcerative colitis (UC) (20.5% vs. 15.4%, P = 0.003). Joint manifestations (10.0%) and aphthous ulcers (5.5%) were most common, with aphthous ulcers significantly more frequent in CD (11.2% vs. 2.8%, P < 0.001). The prevalence of classic EIMs such as arthritis/arthralgia (8.0%), uveitis (0.5%), and erythema nodosum (0.9%) fell within the low-to-mid range of global reports. Significant co-occurrence was observed among EIMs. For example, arthritis/arthralgia showed strong associations with uveitis (OR = 31.88) and erythema nodosum (OR = 13.34). Analysis of medication history revealed higher use of infliximab in patients with arthritis/arthralgia (47.0%) and pyoderma gangrenosum (71.4%), and frequent glucocorticoid use in those with venous thromboembolism (72.4%). In this inpatient-based cohort, the lower prevalence of classic EIMs in Chinese IBD patients may reflect clinical underdetection or genuine epidemiological differences. EIMs can precede intestinal symptoms and influence each other, underscoring the need for proactive, systematic assessment in clinical practice.

  • Open Access

    When intestinal ulceration meets hematologic malignancies: clinical features and mortality from a pooled individual-patient data systematic review

    by Song Su, He Zhou, Zimeng Wang, Yanting Shi, Xiaofei Li, Longsong Li, Yawei Bi, Jie Liang, Ningli Chai

    Background and aims: Intestinal ulceration with pancytopenia is rare but associated with high mortality, reported mostly in small case series. It often occurs in patients with inflammatory bowel disease (IBD) or intestinal Behçet’s disease (BD) and concurrent myelodysplastic syndrome (MDS) or aplastic anemia (AA). We performed a systematic review and pooled individual−patient data analysis to characterize the clinical features, evaluate mortality, and explore prognostic factors. Methods: We searched PubMed, Embase, ClinicalTrials.gov, and PROSPERO from database inception to November 10, 2025, for eligible case reports, case series, and cohort studies. Individual patient data were extracted and pooled to describe clinical features and evaluate mortality. Cox proportional hazards models were used to assess factors associated with mortality. Results: Sixty studies (128 patients) were included. In patients with BD and MDS, a marked female predominance (68.9%) and a high prevalence of trisomy 8 (85.7%) were observed, with ulcers predominantly located in the ileocecal region. In IBD-associated cases, patients with pancytopenia were characterized by a strong male preponderance (up to 90%) and rare trisomy 8 abnormalities; intestinal involvement typically manifested as ileal ulcers in Crohn’s disease (CD) and pancolitis in ulcerative colitis (UC). Diagnoses were frequently concurrent, or intestinal symptoms preceded the onset of hematologic disease. Overall mortality was substantial, ranging from 31.3% to 44.4%. In subgroup analyses, male sex and MDS evolution were associated with higher mortality in patients with BD and MDS, while high-risk MDS subtypes were linked to poorer survival in those with IBD and MDS. Conclusion: The coexistence of intestinal ulcers and pancytopenia is associated with substantial mortality, reaching as high as 44.4%. The observed sex distribution and trisomy 8 patterns should be interpreted as hypothesis-generating clinical clues rather than definitive evidence of pathogenic significance or diagnostic utility. By systematically characterizing the clinical features and prognosis of this rare condition, this study provides a useful synthesis of the available evidence and highlights priorities for future prospective and mechanistic studies. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020165205 , identifier CRD42020165205.

  • Open Access

    Discrepancies between patients’ and gastroenterologists’ perceptions of diagnosis and treatment in ulcerative colitis: a multicenter retrospective study

    by Zhenzhen Fan, Ruixia Li, Xin Liu, Qian Cao, Weiming Zhu, Minhu Chen, Yihong Fan, Naizhong Hu, Yufang Wang, Xiaoping Lv, et al.

    Background: Ulcerative colitis (UC), a chronic and relapsing inflammatory bowel disease, has long depended on physician-led objective evaluations for clinical management. However, physicians’ assessments of symptoms often differ from patients’ subjective experiences, creating a cognitive gap that may influence treatment decisions and overall disease outcomes. Objective: This study aimed to compare the cognitive discrepancy between UC patients and gastroenterologists throughout the diagnosis and treatment process. Design: Multicenter retrospective study. Methods: A nationwide survey was conducted across 39 Inflammatory Bowel Disease centers in China using a convenience sampling method, enrolling 457 UC patients and 170 gastroenterologists. A two-way questionnaire survey was administered to both groups to assess perceptions of disease status, treatment goals, medication use, follow-up preferences, economic burden, and decision-making models. Results: This multicenter study identified significant cognitive gaps between UC patients and gastroenterologists across key domains of disease management. Physicians prioritized objective clinical indicators such as hematochezia (51.18% vs 41.58%, p = 0.031), whereas patients emphasized subjective symptoms like rectal urgency (19.69% vs 4.12%, p < 0.001). Treatment goals also differed: patients valued quality-of-life improvement most, while physicians ranked endoscopic mucosal healing highest. Discrepancies extended to follow-up, with physicians favoring bi-monthly visits and patients preferring intervals exceeding 6 months. In decision-making, although 47.06% of physicians supported shared decision-making, only 10.72% of patients endorsed this model ( p < 0.001). Notably, patients’ willingness to allocate >50% of household income to treatment (21.44%) substantially surpassed physicians’ expectations (5.29%, p < 0.001). Conclusion: These findings indicate a clear disconnect between current clinical management approaches and the lived experience of patients with UC in China. To bridge this gap, practice must shift toward models that actively integrate patient priorities into treatment plans.

  • Open Access

    Dual-targeted therapy for the management of refractory Crohn’s disease: a retrospective cohort study

    by Jindan He, Jiaqi Zhang, He Zhou, Yu Da, Xiaoning Liu, Tiantian Zhang, Zhenzhen Fan, Tong Wu, Yanting Shi, Jie Liang

    Crohn’s disease (CD) is a chronic relapsing autoimmune disease. Dual-targeted therapy (DTT) has been proven effective and safe in refractory inflammatory bowel disease (IBD), especially the combination of ustekinumab with vedolizumab (UST + VDZ). However, the efficacy and safety of DTT on refractory CD are still limited or insufficient. We aim to evaluate the efficacy and safety of DTT including ustekinumab combined with adalimumab (UST + ADA) and UST + VDZ in refractory CD patients. Refractory CD patients who failed at least two biologics from Xijing IBD Center were included. Clinical evaluation was performed by Crohn’s Disease Activity Index (CDAI). Endoscopic data were assessed using Simple Endoscopic Score-Crohn’s Disease (SES-CD). Other clinical indicators were also collected. Totally, 23 patients were enrolled, and 20 completed 4–27 months of follow-up. Among these patients, there were significant post-treatment reductions in median SES-CD [14.5–5 (p < 0.005)] and CDAI [326.25–94.75 (p < 0.005)]. For UST + ADA (n = 16), 68.75% reached endoscopic response, 56.25% achieved endoscopic remission, 75% clinical response occurred, and 68.75% of patients achieved clinical remission. For UST + VDZ (n = 4), 25% had endoscopic response, 50% had clinical response, and one achieved clinical remission. The regimen of UST + ADA exhibited a more favorable performance during follow-up. 7 patients discontinued DTT due to no significant improvement or exacerbation, and no severe adverse events were observed. The study supports the effectiveness and safety of DTT for refractory CD and especially suggests the potential efficacy and safety of UST + ADA. Larger sample and randomized controlled trial (RCT) studies are needed for confirmation.


  • Open Access

    Different perceptions on the diagnosis and treatment of Crohn’s disease between patients and gastroenterologists: a multicenter retrospective study

    by Zhenzhen Fan, Ruixia Li, Xiaoqi Zhang, Minhu Chen, Qian Cao, Yihong Fan, Fang Xiao, Yufang Wang, Liangru Zhu, Hong Guo, et al.

    Background: Physician assessments of patient symptoms may not align with the patients’ subjective experiences, potentially affecting disease management. The key drivers of patients with Crohn’s disease (CD) regarding their physicians’ engagement in treatment decision-making are unknown. Objective: This study aimed to compare cognitive differences between patients and gastroenterologists in the diagnostic and treatment processes of CD. Design: Retrospective multicenter study. Methods: This study was conducted at 39 inflammatory bowel disease (IBD) centers across China, ultimately recruiting 601 patients with CD and 181 gastroenterologists. Results: Regarding symptom focus, physicians were more concerned about abdominal pain, while patients, particularly inpatients, were more concerned about frequent medical visits. There were also significant differences in the treatment goals. Patients prioritized improving their quality of life, whereas physicians showed a hierarchical difference in their focus: resident and attending physicians emphasized mucosal healing, while deputy chief physicians and above placed greater importance on long-term remission (clinical, endoscopic, and histological). Regarding knowledge gaps about CD, physicians significantly overestimated patients’ understanding of biologics (93.37% vs 71.55%, κ = 0.117), with inpatients showing slightly higher awareness than outpatients (73.96% vs 70.42%). Regarding follow-up compliance, the discrepancy was especially prominent: 46.96% of physicians recommended follow-up every ⩽2 months, while 61.73% of patients preferred follow-up every 6 months. The economic burden of CD revealed that 21.30% of patients were willing to spend over 50% of their household income on treatment, which far exceeded physicians’ expectations (9.94%). Lastly, there was a significant divergence in decision-making models: 49.17% of physicians advocated for shared decision-making, but only 14.31% of patients agreed with this model (κ = 0.353). Conclusion: There are notable cognitive disparities between patients with CD and physicians in their approaches to disease management, particularly concerning follow-up frequency and treatment options. These differences underscore the need for targeted interventions to bridge the gap between patient and physician perspectives. Therefore, future research should focus on enhancing communication between doctors and patients and enabling them to play a more active role in health management and treatment decisions.